InNexus Biotechnology, Inc. (TSXV:IXS) announced an equity line of credit transaction for gross proceeds of CAD 7,500,000 on May 30, 2008. The company will issue common shares over a period of 60 months. The investor may purchase common shares equal in amount to the lesser of, CAD 125,000 for each advance, or the remaining portion of the commitment amount at a price equal at 95% of the daily volume weighted average price of the common shares on the trading day prior to the notice date. The investor is also entitled to reduce the amount of each advance by 10% for each day during the 10 trading days following the notice date if the company's weighted average price is less than the purchase price for that advance.

The transaction was cancelled as on May 30, 2013.